Salvage therapy at biochemical recurrence of prostate cancer - PubMed (original) (raw)

Comment

Salvage therapy at biochemical recurrence of prostate cancer

Nicholas G Zaorsky et al. Nat Rev Urol. 2020 Apr.

No abstract available

Salvage Radiotherapy Versus Hormone Therapy for Prostate-specific Antigen Failure After Radical Prostatectomy: A Randomised, Multicentre, Open-label, Phase 3 Trial (JCOG0401)†.
Yokomizo A, Wakabayashi M, Satoh T, Hashine K, Inoue T, Fujimoto K, Egawa S, Habuchi T, Kawashima K, Ishizuka O, Shinohara N, Sugimoto M, Yoshino Y, Nihei K, Fukuda H, Tobisu KI, Kakehi Y, Naito S; JCOG0401 Investigators. Yokomizo A, et al. Eur Urol. 2020 Jun;77(6):689-698. doi: 10.1016/j.eururo.2019.11.023. Epub 2019 Dec 19. Eur Urol. 2020. PMID: 31866092 Clinical Trial.

1. Yokomizo, A. et al. Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-label, phase 3 trial (JCOG0401). Eur. Urol. https://doi.org/10.1016/j.eururo.2019.11.023 (2019). -DOI -PubMed
1. Zaorsky, N. G. et al. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer. Future Oncol. 10, 457–474 (2014). -DOI
1. Calais, J. et al. (18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 20, 1286–1294 (2019). -DOI
1. Panebianco, V. et al. Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur. Radiol. 23, 1745–1752 (2013). -DOI
1. Tendulkar, R. D. et al. Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J. Clin. Oncol. 34, 3648–3654 (2016). -DOI